` CLNN (Clene Inc.) vs S&P 500 Comparison - Alpha Spread

CLNN
vs
S&P 500

Over the past 12 months, CLNN has significantly outperformed S&P 500, delivering a return of +42% compared to the S&P 500's +14% growth.

Stocks Performance
CLNN vs S&P 500

Loading
CLNN
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CLNN vs S&P 500

Loading
CLNN
S&P 500
Difference
www.alphaspread.com

Performance By Year
CLNN vs S&P 500

Loading
CLNN
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Clene Inc. vs Peers

S&P 500
CLNN
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Clene Inc.
Glance View

Market Cap
68.3m USD
Industry
Biotechnology

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 95 full-time employees. The company went IPO on 2018-08-27. The firm is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The firm has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.

CLNN Intrinsic Value
27.01 USD
Undervaluation 75%
Intrinsic Value
Price
Back to Top